PUMA BIOTECHNOLOGY, INC. Note Agreements
7 Contracts & Agreements
- Seventh Amendment to Note Purchase Agreement and Third Amendment to Disclosure Letter, dated April 12, 2024, by and between the Company and Athyrium Opportunities IV CO-Invest 1... (Filed With SEC on May 2, 2024)
- Sixth Amendment to Note Purchase Agreement, dated September 8, 2023, by and between the Company and Athyrium Opportunities IV CO-Invest 1 LP, as Administrative Agent (Filed With SEC on November 2, 2023)
- Limited Waiver and Fifth Amendment to Note Purchase Agreement, dated July 7, 2023, by and between the Company and Athyrium Opportunities IV CO-Invest 1 LP, as Administrative Agent (Filed With SEC on August 3, 2023)
- Fourth Amendment to Note Purchase Agreement, dated November29, 2022,by and between the Company and Athyrium Opportunities IV CO-Invest 1 LP, as Administrative Agent (Filed With SEC on March 2, 2023)
- Second Amendment to Note Purchase Agreement, dated May 18, 2022,by and between the Company and Athyrium Opportunities IV CO-Invest 1 LP, as Administrative Agent (Filed With SEC on March 2, 2023)
- Third Amendment to Note Purchase Agreement, dated September 16, 2022, by and between the Company and Athyrium Opportunities IV Co-Invest 1 LP, as Administrative Agent (Filed With SEC on November 3, 2022)
- First Amendment to Note Purchase Agreement, dated February 8, 2022, by and between the Company and Athyrium Opportunities IV CO-Invest 1 LP, as Administrative Agent (Filed With SEC on March 3, 2022)
